Trial reportThe international journal of neuropsychopharmacology2016
Agomelatine Increases BDNF Serum Levels in Depressed Patients in Correlation with the Improvement of Depressive Symptoms.
Open access · goldAbstract readRandomized Controlled Trial
In one paragraph
Trial report in The international journal of neuropsychopharmacology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed, 2 pooled it
7.1field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 2 syntheses or guidelines pooled it, 97 citations in OpenAlex.
- Probiotics for the treatment of depression and its comorbidities: A systemic review.Frontiers in cellular and infection microbiology · 2023Pooled it
- The Efficacy of Non-Pharmacological Interventions on Brain-Derived Neurotrophic Factor in Schizophrenia: A Systematic Review and Meta-Analysis.International journal of molecular sciences · 2016Pooled it
- Neurotrophin System as a Complex Set of Potential Biomarkers in Psychiatric Disorders and Therapy-Overview of Recent Advances.International journal of molecular sciences · 2026Review
- Childhood abuse moderates the impact of serum BDNF on short- and long-term antidepressant response.European child & adolescent psychiatry · 2026Article
- Review
- Improving executive functioning and reducing the risk of Alzheimer's disease with music therapy: A narrative review of potential neural mechanisms.Journal of Alzheimer's disease : JAD · 2025Review
- The characteristics of anhedonia in depression: a review from a clinically oriented perspective.Translational psychiatry · 2025Review
- Anhedonia: Current and future treatments.PCN reports : psychiatry and clinical neurosciences · 2025Review
- Efficacy of Serum BDNF for the Evaluation of Depressive Neurological Symptoms in Patients with Refractory Ulcerative Colitis.Journal of clinical medicine · 2025Article
- Disease-Modifying Symptomatic Treatment (DMST): The Potential Role of Vortioxetine in the Treatment of Depression in Patients with Multiple Sclerosis.Current neuropharmacology · 2025Review
- Review
- Potential biomarkers and therapeutic targets for obsessive compulsive disorder: Evidences from clinical studies.Biochemia medica · 2024Review
- Anhedonia and Depressive Disorders.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2023Review
- Agomelatine: a potential novel approach for the treatment of memory disorder in neurodegenerative disease.Neural regeneration research · 2023Review
- Article
- Increased academic stress is associated with decreased plasma BDNF in Chilean college students.PeerJ · 2023Article
- Pharmacological Treatments for Anhedonia.Current topics in behavioral neurosciences · 2022Article
- BDNF and Cortisol in the Diagnosis of Cocaine-Induced Depression.Frontiers in psychiatry · 2022Article
- The Role of Natural Products in Treatment of Depressive Disorder.Current neuropharmacology · 2022Article
- Linalool as a Therapeutic and Medicinal Tool in Depression Treatment: A Review.Current neuropharmacology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Giovanni MartinottiDepartment of Neuroscience, Imaging, and Clinical Sciences, University "G.d'Annunzio", Chieti, Italy (Drs Martinotti, De Berardis, and Di Giannantonio); Institute of Psychiatry and Psychology, Catholic University of the Sacred Hearth, Rome, Italy (Drs Pettorruso, Di Nicola, and Janiri); Department of Immunohematology and Transfusional Medicine, "G. Mazzini" Hospital, Teramo, Italy (Drs Varasano, Lucidi Pressanti, and De Remigis); Hermanas Hospitalarias, FoRiPsi, Villa S. Giuseppe Hospital, Ascoli Piceno, Italy (Dr Valchera); Department of Psychiatry, ASL Valle d'Aosta, Italy (Dr Ricci); Department of Life and Environmental Sciences, Institute of Neuroscience, CNR, University of Cagliari, Cagliari, Italy (Dr Biggio). giovanni.martinotti@gmail.com.
Mauro PettorrusoDepartment of Neuroscience, Imaging, and Clinical Sciences, University "G.d'Annunzio", Chieti, Italy (Drs Martinotti, De Berardis, and Di Giannantonio); Institute of Psychiatry and Psychology, Catholic University of the Sacred Hearth, Rome, Italy (Drs Pettorruso, Di Nicola, and Janiri); Department of Immunohematology and Transfusional Medicine, "G. Mazzini" Hospital, Teramo, Italy (Drs Varasano, Lucidi Pressanti, and De Remigis); Hermanas Hospitalarias, FoRiPsi, Villa S. Giuseppe Hospital, Ascoli Piceno, Italy (Dr Valchera); Department of Psychiatry, ASL Valle d'Aosta, Italy (Dr Ricci); Department of Life and Environmental Sciences, Institute of Neuroscience, CNR, University of Cagliari, Cagliari, Italy (Dr Biggio).
Domenico De BerardisDepartment of Neuroscience, Imaging, and Clinical Sciences, University "G.d'Annunzio", Chieti, Italy (Drs Martinotti, De Berardis, and Di Giannantonio); Institute of Psychiatry and Psychology, Catholic University of the Sacred Hearth, Rome, Italy (Drs Pettorruso, Di Nicola, and Janiri); Department of Immunohematology and Transfusional Medicine, "G. Mazzini" Hospital, Teramo, Italy (Drs Varasano, Lucidi Pressanti, and De Remigis); Hermanas Hospitalarias, FoRiPsi, Villa S. Giuseppe Hospital, Ascoli Piceno, Italy (Dr Valchera); Department of Psychiatry, ASL Valle d'Aosta, Italy (Dr Ricci); Department of Life and Environmental Sciences, Institute of Neuroscience, CNR, University of Cagliari, Cagliari, Italy (Dr Biggio).
Paola Annunziata VarasanoDepartment of Neuroscience, Imaging, and Clinical Sciences, University "G.d'Annunzio", Chieti, Italy (Drs Martinotti, De Berardis, and Di Giannantonio); Institute of Psychiatry and Psychology, Catholic University of the Sacred Hearth, Rome, Italy (Drs Pettorruso, Di Nicola, and Janiri); Department of Immunohematology and Transfusional Medicine, "G. Mazzini" Hospital, Teramo, Italy (Drs Varasano, Lucidi Pressanti, and De Remigis); Hermanas Hospitalarias, FoRiPsi, Villa S. Giuseppe Hospital, Ascoli Piceno, Italy (Dr Valchera); Department of Psychiatry, ASL Valle d'Aosta, Italy (Dr Ricci); Department of Life and Environmental Sciences, Institute of Neuroscience, CNR, University of Cagliari, Cagliari, Italy (Dr Biggio).
Gabriella Lucidi PressantiDepartment of Neuroscience, Imaging, and Clinical Sciences, University "G.d'Annunzio", Chieti, Italy (Drs Martinotti, De Berardis, and Di Giannantonio); Institute of Psychiatry and Psychology, Catholic University of the Sacred Hearth, Rome, Italy (Drs Pettorruso, Di Nicola, and Janiri); Department of Immunohematology and Transfusional Medicine, "G. Mazzini" Hospital, Teramo, Italy (Drs Varasano, Lucidi Pressanti, and De Remigis); Hermanas Hospitalarias, FoRiPsi, Villa S. Giuseppe Hospital, Ascoli Piceno, Italy (Dr Valchera); Department of Psychiatry, ASL Valle d'Aosta, Italy (Dr Ricci); Department of Life and Environmental Sciences, Institute of Neuroscience, CNR, University of Cagliari, Cagliari, Italy (Dr Biggio).
Valeria De RemigisDepartment of Neuroscience, Imaging, and Clinical Sciences, University "G.d'Annunzio", Chieti, Italy (Drs Martinotti, De Berardis, and Di Giannantonio); Institute of Psychiatry and Psychology, Catholic University of the Sacred Hearth, Rome, Italy (Drs Pettorruso, Di Nicola, and Janiri); Department of Immunohematology and Transfusional Medicine, "G. Mazzini" Hospital, Teramo, Italy (Drs Varasano, Lucidi Pressanti, and De Remigis); Hermanas Hospitalarias, FoRiPsi, Villa S. Giuseppe Hospital, Ascoli Piceno, Italy (Dr Valchera); Department of Psychiatry, ASL Valle d'Aosta, Italy (Dr Ricci); Department of Life and Environmental Sciences, Institute of Neuroscience, CNR, University of Cagliari, Cagliari, Italy (Dr Biggio).
Alessandro ValcheraDepartment of Neuroscience, Imaging, and Clinical Sciences, University "G.d'Annunzio", Chieti, Italy (Drs Martinotti, De Berardis, and Di Giannantonio); Institute of Psychiatry and Psychology, Catholic University of the Sacred Hearth, Rome, Italy (Drs Pettorruso, Di Nicola, and Janiri); Department of Immunohematology and Transfusional Medicine, "G. Mazzini" Hospital, Teramo, Italy (Drs Varasano, Lucidi Pressanti, and De Remigis); Hermanas Hospitalarias, FoRiPsi, Villa S. Giuseppe Hospital, Ascoli Piceno, Italy (Dr Valchera); Department of Psychiatry, ASL Valle d'Aosta, Italy (Dr Ricci); Department of Life and Environmental Sciences, Institute of Neuroscience, CNR, University of Cagliari, Cagliari, Italy (Dr Biggio).
Valerio RicciDepartment of Neuroscience, Imaging, and Clinical Sciences, University "G.d'Annunzio", Chieti, Italy (Drs Martinotti, De Berardis, and Di Giannantonio); Institute of Psychiatry and Psychology, Catholic University of the Sacred Hearth, Rome, Italy (Drs Pettorruso, Di Nicola, and Janiri); Department of Immunohematology and Transfusional Medicine, "G. Mazzini" Hospital, Teramo, Italy (Drs Varasano, Lucidi Pressanti, and De Remigis); Hermanas Hospitalarias, FoRiPsi, Villa S. Giuseppe Hospital, Ascoli Piceno, Italy (Dr Valchera); Department of Psychiatry, ASL Valle d'Aosta, Italy (Dr Ricci); Department of Life and Environmental Sciences, Institute of Neuroscience, CNR, University of Cagliari, Cagliari, Italy (Dr Biggio).
Marco Di NicolaDepartment of Neuroscience, Imaging, and Clinical Sciences, University "G.d'Annunzio", Chieti, Italy (Drs Martinotti, De Berardis, and Di Giannantonio); Institute of Psychiatry and Psychology, Catholic University of the Sacred Hearth, Rome, Italy (Drs Pettorruso, Di Nicola, and Janiri); Department of Immunohematology and Transfusional Medicine, "G. Mazzini" Hospital, Teramo, Italy (Drs Varasano, Lucidi Pressanti, and De Remigis); Hermanas Hospitalarias, FoRiPsi, Villa S. Giuseppe Hospital, Ascoli Piceno, Italy (Dr Valchera); Department of Psychiatry, ASL Valle d'Aosta, Italy (Dr Ricci); Department of Life and Environmental Sciences, Institute of Neuroscience, CNR, University of Cagliari, Cagliari, Italy (Dr Biggio).
Luigi JaniriDepartment of Neuroscience, Imaging, and Clinical Sciences, University "G.d'Annunzio", Chieti, Italy (Drs Martinotti, De Berardis, and Di Giannantonio); Institute of Psychiatry and Psychology, Catholic University of the Sacred Hearth, Rome, Italy (Drs Pettorruso, Di Nicola, and Janiri); Department of Immunohematology and Transfusional Medicine, "G. Mazzini" Hospital, Teramo, Italy (Drs Varasano, Lucidi Pressanti, and De Remigis); Hermanas Hospitalarias, FoRiPsi, Villa S. Giuseppe Hospital, Ascoli Piceno, Italy (Dr Valchera); Department of Psychiatry, ASL Valle d'Aosta, Italy (Dr Ricci); Department of Life and Environmental Sciences, Institute of Neuroscience, CNR, University of Cagliari, Cagliari, Italy (Dr Biggio).
Giovanni BiggioDepartment of Neuroscience, Imaging, and Clinical Sciences, University "G.d'Annunzio", Chieti, Italy (Drs Martinotti, De Berardis, and Di Giannantonio); Institute of Psychiatry and Psychology, Catholic University of the Sacred Hearth, Rome, Italy (Drs Pettorruso, Di Nicola, and Janiri); Department of Immunohematology and Transfusional Medicine, "G. Mazzini" Hospital, Teramo, Italy (Drs Varasano, Lucidi Pressanti, and De Remigis); Hermanas Hospitalarias, FoRiPsi, Villa S. Giuseppe Hospital, Ascoli Piceno, Italy (Dr Valchera); Department of Psychiatry, ASL Valle d'Aosta, Italy (Dr Ricci); Department of Life and Environmental Sciences, Institute of Neuroscience, CNR, University of Cagliari, Cagliari, Italy (Dr Biggio).
Massimo Di GiannantonioDepartment of Neuroscience, Imaging, and Clinical Sciences, University "G.d'Annunzio", Chieti, Italy (Drs Martinotti, De Berardis, and Di Giannantonio); Institute of Psychiatry and Psychology, Catholic University of the Sacred Hearth, Rome, Italy (Drs Pettorruso, Di Nicola, and Janiri); Department of Immunohematology and Transfusional Medicine, "G. Mazzini" Hospital, Teramo, Italy (Drs Varasano, Lucidi Pressanti, and De Remigis); Hermanas Hospitalarias, FoRiPsi, Villa S. Giuseppe Hospital, Ascoli Piceno, Italy (Dr Valchera); Department of Psychiatry, ASL Valle d'Aosta, Italy (Dr Ricci); Department of Life and Environmental Sciences, Institute of Neuroscience, CNR, University of Cagliari, Cagliari, Italy (Dr Biggio).
Azienda USL della Valle d’Aosta · ITUniversity of Chieti-Pescara · ITUniversità Cattolica del Sacro Cuore · IT
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAgomelatine modulates brain-derived neurotrophic factor expression via its interaction with melatonergic and serotonergic receptors and has shown promising results in terms of brain-derived neurotrophic factor increase in animal models.
methodsTwenty-seven patients were started on agomelatine (25mg/d). Venous blood was collected and brain-derived neurotrophic factor serum levels were measured at baseline and after 2 and 8 weeks along with a clinical assessment, including Hamilton Depression Rating Scale and Snaith-Hamilton Pleasure Scale.
resultsBrain-derived neurotrophic factor serum concentration increased after agomelatine treatment. Responders showed a significant increase in brain-derived neurotrophic factor levels after 2 weeks of agomelatine treatment; no difference was observed in nonresponders. Linear regression analysis showed that more prominent brain-derived neurotrophic factor level variation was associated with lower baseline BDNF levels and greater anhedonic features at baseline.
conclusionsPatients affected by depressive disorders showed an increase of brain-derived neurotrophic factor serum concentration after a 2-week treatment with agomelatine. The increase of brain-derived neurotrophic factor levels was found to be greater in patients with lower brain-derived neurotrophic factor levels and marked anhedonia at baseline.
Indexed as
AcetamidesAffectAgedAntidepressive AgentsBiomarkersBrain-Derived Neurotrophic FactorDepressionFemaleHumansItalyLinear ModelsMaleMiddle AgedNaphthalenesRemission InductionTime FactorsAcetamidesagomelatineAntidepressive AgentsBDNF protein, humanBiomarkersBrain-Derived Neurotrophic FactorNaphthalenesagomelatineBDNFmajor depressive disorder
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.